Dynavax Technologies Corporation (DVAX)
NASDAQ: DVAX · Real-Time Price · USD
9.85
+0.44 (4.68%)
At close: May 12, 2025, 4:00 PM
9.87
+0.02 (0.20%)
After-hours: May 12, 2025, 7:47 PM EDT
Dynavax Technologies Revenue
Dynavax Technologies had revenue of $68.16M in the quarter ending March 31, 2025, with 34.21% growth. This brings the company's revenue in the last twelve months to $294.62M, up 24.76% year-over-year. In the year 2024, Dynavax Technologies had annual revenue of $277.25M with 19.36% growth.
Revenue (ttm)
$294.62M
Revenue Growth
+24.76%
P/S Ratio
4.30
Revenue / Employee
$727,457
Employees
405
Market Cap
1.18B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 277.25M | 44.96M | 19.36% |
Dec 31, 2023 | 232.28M | -490.40M | -67.86% |
Dec 31, 2022 | 722.68M | 283.24M | 64.45% |
Dec 31, 2021 | 439.44M | 399.19M | 991.75% |
Dec 31, 2020 | 40.25M | 5.03M | 14.29% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
DVAX News
- 15 hours ago - Dynavax Files Investor Presentation Highlighting Superior Strategy and Board That is Delivering Strong Financial Results and Significant Long-Term Value - PRNewsWire
- 5 days ago - Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum - PRNewsWire
- 6 days ago - Dynavax Technologies Corporation (DVAX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs - PRNewsWire
- 6 days ago - Deep Track Capital Releases Investor Presentation on Dynavax Technologies - Business Wire
- 11 days ago - Dynavax Announces Nationwide Harris Poll Survey Results Finding Americans Underestimate the Serious Consequences of Hepatitis B and Vaccine Protection Benefits - PRNewsWire
- 13 days ago - Dynavax Highlights Superior Board Leadership Overseeing Long-Term Value Creation Strategy - PRNewsWire
- 20 days ago - Dynavax to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025 - PRNewsWire